Anbio Biotechnology
NNNN
$6.61
$0.040.61%
NASDAQ
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 0.00% | 390.67% | 0.00% | -51.80% | 0.00% |
| Total Depreciation and Amortization | -- | -- | 0.00% | -63.64% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 0.00% | 5.99% | 0.00% | -796.34% | 0.00% |
| Change in Net Operating Assets | 0.00% | -56.89% | 0.00% | -394.63% | 0.00% |
| Cash from Operations | 0.00% | 148.57% | 0.00% | -157.85% | 0.00% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 0.00% | -5.99% | 0.00% | -90.72% | 0.00% |
| Cash from Investing | 0.00% | -5.99% | 0.00% | -90.72% | 0.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 0.00% | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00% | -153.99% | 0.00% | 183.27% | 0.00% |
| Cash from Financing | 0.00% | -153.90% | 0.00% | 183.27% | 0.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 0.00% | 171.28% | 0.00% | -125.24% | 0.00% |